Weight-Loss Medication Denied by a Health Plan
What can I do if a plan denies a weight-loss medication?
A plan can deny a drug such as Wegovy or Zepbound when the prescription is for weight loss. The notice may say the drug is not on the formulary, that weight-loss drugs are excluded, that an approval was missing, or that the use is not medically necessary. Medicare Part D generally does not cover a drug when it is used for weight loss. CMS also describes other uses a Part D plan may cover, and a separate program for some weight-loss prescriptions. This page explains those paths. It does not promise that the drug will be covered.
Get help with my bill →What should I read on a weight-loss drug denial?
The points below were checked on HealthCare.gov, eCFR, CMS, Medicare.gov, and the FDA labels linked in this guide on November 15, 2026. The denial notice controls the reason and the deadline for your drug.
Read the notice for the drug name, the strength, and the reason. Not on the formulary, a plan exclusion for weight-loss drugs, a missing approval, step therapy, and not medically necessary are different problems. HealthCare.gov defines a formulary as the plan's drug list. HealthCare.gov says prior authorization is a decision about whether a service is medically necessary, and that it is not a promise of payment. It does not add a benefit the plan leaves out. Ask the plan, in writing, to point to the exclusion or the rule it used. Do not change or stop a medicine on your own. Ask the prescriber what to do if you may run out.
A missing approval is in a prior authorization denial. Step therapy is in a step therapy denial. A drug left off the list is in a prescription drug the plan will not cover. The same drugs can also be denied for a use other than weight loss. That broader denial is in a specialty medication denied by insurance. Surgery for weight loss is a different denial. See a bariatric surgery denial.
References: HealthCare.gov: Formulary · HealthCare.gov: Preauthorization · HealthCare.gov: Internal appeals
Can I ask for a formulary exception?
Sometimes. 45 CFR 156.122(c) applies to a health plan that provides essential health benefits. It is a process for you, your designee, or your prescriber to ask for a clinically appropriate drug the plan does not otherwise cover. HealthCare.gov describes essential health benefits as a set of 10 categories of services plans must cover, and it names prescription drug coverage as one of them. A plan that does not provide essential health benefits, which can include some large employer plans, may not use this section. Ask the plan whether it provides those benefits. If the notice gives a different process, follow the notice.
For a standard exception, the plan must decide and send notice no later than 72 hours after it receives the request. For an expedited request, the plan must decide and send notice no later than 24 hours after it receives the request. Those hours are the plan's time to decide. They are not your deadline to file. If the plan grants the exception, it must treat the drug as an essential health benefit, including counting cost sharing toward the annual limit. If the plan denies the exception, you can ask for the external review described in that same section. The full clocks, including that external review, are in a prescription drug the plan will not cover.
An exception asks for a drug the plan does not list. It is not, by itself, a way to add a benefit the plan document excludes. If the denial says the plan does not cover weight-loss drugs at all, ask the plan to show that sentence in the plan document. Then follow the appeal on the notice. A job-based plan's internal appeal, when the Department of Labor rule applies, is explained in how to appeal a health insurance denial. External review of a medical-necessity denial is in how to request an external review. A denial that only says the benefit is not offered may not qualify for that external review. The notice is the practical answer.
References: 45 CFR 156.122: Essential health benefit prescription drug exceptions · HealthCare.gov: Essential health benefits, including pediatric dental · HealthCare.gov: Internal appeals · HealthCare.gov: External review · 45 CFR 147.136: Internal claims, appeals, and external review
What if the prescription is for a use other than weight loss?
Ask the prescriber which use is on the prescription, and ask the prescriber to name that use in the request to the plan. The FDA label for Wegovy includes use to reduce the risk of cardiovascular death, heart attack, or stroke in adults with established cardiovascular disease and obesity or overweight. The FDA label for Zepbound includes moderate to severe obstructive sleep apnea in adults with obesity. Ozempic and Mounjaro are approved to improve blood sugar in adults with type 2 diabetes, with diet and exercise. Those uses are different from weight loss alone. The prescriber, not this page, decides which use fits the prescription. If that prescription is Ozempic, Mounjaro, or another GLP-1 for type 2 diabetes, see a diabetes medication denial.
If the plan covers the drug for the use on the prescription, the request is about that use. Send the records that match it. If the plan still says the drug is not on the list, use the exception process above or the Part D process below, whichever the notice names.
References: FDA: Wegovy (semaglutide) prescribing information · FDA: Zepbound (tirzepatide) prescribing information · FDA: Ozempic (semaglutide) prescribing information · FDA: Mounjaro (tirzepatide) prescribing information
Does Medicare Part D cover a drug used for weight loss?
Not for weight loss alone. 42 CFR 423.100 leaves weight-loss uses out of the Part D drug definition. That rule points to section 1927(d)(2) of the Social Security Act, which lists agents when used for anorexia, weight loss, or weight gain among drugs that may be excluded. A prescription whose only use is weight loss is generally not a Part D benefit. A Part D appeal does not add that excluded use.
CMS says other uses can be Part D benefits. On the page for Part D plans checked on November 15, 2026, CMS says type 2 diabetes, moderate to severe obstructive sleep apnea, and noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver scarring are eligible for Part D coverage. CMS also names Wegovy, for reducing the risk of major cardiovascular events in adults with established cardiovascular disease and obesity or overweight, as an example of a use that stays with the Part D plan. If the prescription is for one of those uses, ask the Part D plan to cover it, including by a formulary exception if the drug is not on the plan's list. CMS says the plan must keep using its Part D exception process for those requests. The steps and the two ways of counting the redetermination deadline are in a prescription drug the plan will not cover. Medicare.gov says a redetermination is generally due within 65 days of the date on the denial notice. Follow the date on your notice.
References: 42 CFR 423.100: Part D drug definition · Social Security Act section 1927(d)(2): drugs that may be excluded, including weight loss · CMS: Part D coverage of GLP-1 uses and the Medicare GLP-1 Bridge · Medicare.gov: Appeals in Medicare drug plans · CMS: Medicare Part D coverage determinations · CMS: Medicare Part D exceptions
What is the Medicare GLP-1 Bridge?
CMS runs a separate program, the Medicare GLP-1 Bridge, from July 1, 2026, through December 31, 2027. CMS says it is outside the Part D benefit. Part D plans do not have to opt in. Medicare.gov says it is for certain people who have Medicare drug coverage and who meet the program's rules. Medicare.gov names three drugs for this program: Foundayo tablets, Wegovy as an injection or a tablet, and Zepbound KwikPen only. Medicare.gov says the program does not cover single-dose Zepbound vials or pens.
Medicare.gov says you must be 18 or older and, when you start the therapy, meet one of these: a body mass index of 35 or higher; a body mass index of 30 or higher plus diastolic heart failure, uncontrolled high blood pressure, or chronic kidney disease at stage 3a or higher; or a body mass index of 27 or higher plus prediabetes, a previous heart attack or stroke, or blocked arteries in the legs or arms that cause symptoms. Medicare.gov says you are not eligible if you already get GLP-1 drugs through your Part D plan, or if you have type 2 diabetes, moderate to severe sleep apnea, or fatty liver disease. It says your Part D plan might still cover the drug for those conditions. CMS says a prescription meant to reduce the risk of major cardiovascular events should go to the Part D plan, even if weight loss is also a goal. If the prescription is only to reduce excess weight, Medicare.gov describes the Bridge for people who meet the rules above.
Medicare.gov says your prescriber sends the prescription to the pharmacy and, when asked, completes a prior authorization. The prescriber must certify that you are using the drug as part of a lifestyle program that focuses on diet and exercise. Medicare.gov says you pay a $50 copay for a one-month supply, either 28 or 30 days depending on the drug. Because a separate program pays, Medicare.gov says that copay does not count toward the Part D deductible or out-of-pocket limit, does not appear on a Part D explanation of benefits, and does not appear on a Medicare Summary Notice. Extra Help and the Medicare Prescription Payment Plan do not lower or spread that copay. Medicare.gov says the prior authorization, including refills and dose changes, is valid through December 31, 2027 unless you change GLP-1 drugs. Medicare.gov says you can call 1-800-MEDICARE with a question about eligibility or the status of the prior authorization. CMS has not, on the page checked November 15, 2026, described this weight-loss coverage as a Part D benefit after December 31, 2027.
References: Medicare.gov: Weight loss drugs and the Medicare GLP-1 Bridge · CMS: Part D coverage of GLP-1 uses and the Medicare GLP-1 Bridge
What this page cannot promise
This is general information, not medical or legal advice. A plan can show an exclusion and leave it in place. An exception can be denied. A Part D plan can deny a use that is not a Part D benefit. The Medicare GLP-1 Bridge has age, body-mass, diagnosis, and drug rules, and it ends on the date CMS states. Nothing on this page promises that a plan, Medicare, or the Bridge will cover a weight-loss drug or cancel a bill.
Sources and further help
These sources provide general guidance. For a deadline or requirement that applies to you, follow your plan’s notice or the appropriate program’s current instructions.
- HealthCare.gov: Formulary ↗
- HealthCare.gov: Preauthorization ↗
- HealthCare.gov: Essential health benefits, including pediatric dental ↗
- 45 CFR 156.122: Essential health benefit prescription drug exceptions ↗
- HealthCare.gov: Internal appeals ↗
- HealthCare.gov: External review ↗
- 45 CFR 147.136: Internal claims, appeals, and external review ↗
- 42 CFR 423.100: Part D drug definition ↗
- Social Security Act section 1927(d)(2): drugs that may be excluded, including weight loss ↗
- CMS: Part D coverage of GLP-1 uses and the Medicare GLP-1 Bridge ↗
- Medicare.gov: Weight loss drugs and the Medicare GLP-1 Bridge ↗
- FDA: Wegovy (semaglutide) prescribing information ↗
- FDA: Zepbound (tirzepatide) prescribing information ↗
- FDA: Ozempic (semaglutide) prescribing information ↗
- FDA: Mounjaro (tirzepatide) prescribing information ↗
- Medicare.gov: Appeals in Medicare drug plans ↗
- CMS: Medicare Part D coverage determinations ↗
- CMS: Medicare Part D exceptions ↗
Insurer websites may ask you to select your state or sign in. If a page will not open, use the member services number on your insurance card and ask for the current appeal instructions for your plan.